VKTX

Viking Therapeutics, Inc.

A clinical-stage biopharmaceutical company in San Diego that develops experimental drugs for metabolic and endocrine disorders, including obesity. Its lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being tested as both a weekly injection and a daily pill for weight loss. Founded in 2012 by Brian Lian, a former Wall Street biotech analyst, the company built its early pipeline by licensing programs from Ligand Pharmaceuticals.

CUSIP: 92686J106HealthcareUS2 holders

Ownership Activity Financials Filings

VKTX

VKTX

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders